GlobeNewswire by notified

No. 5 2023 Course of annual general meeting

Share

The annual general meeting (AGM) took due note of the management’s review and discussed and approved the Annual Report 2022 together with the statement by the Executive Board and the Board of Directors and the independent auditors' report.

The AGM then discussed and adopted the Board of Directors’ proposal for:

  • Allocation of profits in accordance with the approved annual report with dividend distribution of DKK 45.00 for each share of DKK 100.
  • Authorisation of the Board of Directors in the period up to the next annual general meeting to potentially distribute extraordinary dividend of up to DKK 50.00 per share.
  • Authorisation of the Board of Directors in the period up to the next annual general meeting to potentially acquire treasury shares in the company of up to 10% of the share capital, provided that the consideration does not deviate by more than 10% from the market price for the company’s class B-shares at the time of acquisition.
  • Amendments to articles 7.1, 9.1, 9.2, 10.4 - 10.6, 11.1, 11.2, 12, 13.1, 13.3, 13.5 and 17.1 of the company’s articles of association.

The amendments comprise, among other things, an extension (until 1 March 2028) of the Board of Directors’ authorisation to carry out capital increases by up to a nominal amount of DKK 64,600,000, an update of the agenda for the annual general meeting as well as clarification and simplification of various provisions. Please refer to the new articles of association, which are available at the company’s website.

  • Amendment to the company’s remuneration policy. The amendments are mainly clarifications but also include that the current system under which members of the Board of Directors may obtain compensation for lost income be amended so that members of the Board of Directors may be paid a fixed remuneration for each board meeting or committee meeting they attend.
  • Approval of the Remuneration Report 2022 by indicative vote.
  • Remuneration to the Board of Directors for 2023: Fixed annual remuneration of unchanged DKK 200,000. In addition to this, members of the Board of Directors will receive DKK 15,000 for each physical board meeting or committee meeting that they attend, and DKK 7,500 for each virtual board meeting or committee meeting that they attend.
  • Election of the following members to the Board of Directors:
    Re-elected were Michael Troensegaard Andersen, Jesper Dalsgaard, Louise Knauer, Peter Bang, Morten Chrone and Katrine Borum.

The following employee representatives make up the remainder of the Board of Directors: Rune Jesper Nielsen, Denise Goldby and Michael Kærgaard Ravn.

  • Re-election of Deloitte, Statsautoriseret Revisionspartnerselskab, CVR no. 33 96 35 56, as auditor.
  • Authorisation of the chair of the meeting to register the resolutions approved by the AGM with the Danish Business Authority.



At the subsequent board meeting, the Board of Directors elected its officers and re-elected Michael Troensegaard Andersen as its chair and Jesper Dalsgaard as its vice chair.

Re-elected for the Audit Committee were Peter Bang, Louise Knauer and Michael Troensegaard Andersen.

Re-elected for the Remuneration Committee were Michael Troensegaard Andersen, Morten Chrone and Louise Knauer.

Re-elected for the Nomination Committee were Jesper Dalsgaard, Michael Troensegaard Andersen, Katrine Borum and Morten Chrone.


Contact:
Chair Michael Troensegaard Andersen - tel. +45 79 30 00 00

IR Director Dennis Callesen – tel. +45 29 92 18 11


FACTS ABOUTSOLAR

Solar is a leading European sourcing and services company mainly within electrical, heating & plumbing and climate & energy solutions. Our core business centres on product sourcing, value-adding services and optimisation of our customers’ businesses.

We facilitate efficiency improvement and provide digital tools that turn our customers into winners. We drive the green transition and provide best-in-class solutions to ensure sustainable use of resources.

Solar Group is headquartered in Denmark, generated revenue of approx. DKK 13.9bn in 2022 and has approx. 3,000 employees. Solar is listed on Nasdaq Copenhagen and operates under the short designation SOLAR B. For more information, please visit www.solar.eu.

Disclaimer
This announcement was published in Danish and English today via Nasdaq Copenhagen. In the event of any inconsistency between the two versions, the Danish version shall prevail.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Årsrapport 202223.3.2023 22:58:17 CET | pressemeddelelse

Selskabsmeddelelse nr. 2 – 2023 København, den 23. marts 2023 Årsrapport 2022 Bestyrelsen i NTR Holding A/S har i dag behandlet og godkendt Selskabets årsrapport for regnskabsåret 2022. Årsrapporten har følgende hovedpunkter: NTR Holding koncernens salg af Daniamant A/S og Daniamant Ltd. blev gennemført den 31. januar 2022. Hovedparten af provenuet fra salget af Daniamant er udbetalt som udbytte. NTR Holding A/S har således i 2022 udbetalt udbytte på i alt DKK 49 pr. aktie, svarende til et samlet udbytte på DKK 121 mio. Bestyrelsen foreslår, at der ikke udloddes yderligere udbytte for 2022. Koncernens resultat af primær drift udviser et underskud på DKK 2,5 mio. (DKK -1,9 mio. i 2021), hvilket er i overensstemmelse med de senest udmeldte resultatforventninger. Koncernens totalindkomst udgør DKK 1,1 mio. Egenkapitalen udgør DKK 12,9 mio., svarende til en indre værdi pr. aktie på DKK 5,2. Bestyrelsen vil fortsat sondere NTR Holding A/S’ strategiske muligheder, herunder for at kapitaliser

Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting23.3.2023 22:40:00 CET | Press release

Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting Luxembourg, March 23, 2023 – The Nomination Committee of Millicom International Cellular S.A. (“Millicom”) announces that Mr. Nicolas Jaeger appointed by Atlas Luxco S.àr.l., has joined the Nomination Committee of Millicom. On March 17, 2023, Atlas Luxco S.àr.l. reported that it holds a 20% shareholding in Millicom. On March 23, 2023 Mr. Nicolas Jaeger joined the Nomination Committee. The Nomination Committee comprises Jan Dworsky, appointed by Swedbank Robur Funds; Viktor Kockberg, appointed by Nordea Investment Funds; Staley Cates, appointed by Southeastern Asset Management, Gerardo Zamorano appointed by Brandes Investment Partners, and Nicolas Jaeger appointed by Atlas Luxco S.àr.l., as well as the Chairman of Millicom’s Board of Directors, José Antonio Ríos García. Information about the work of the Nomination Committee can be found on Millicom’s website. Shareholders wishing to p

GreenMobility issues warrants23.3.2023 22:40:00 CET | Press release

Company Announcement no. 121– 2023 Copenhagen, March23rd, 2023 GreenMobility issues warrants The Board of Directors of GreenMobility A/S S (“GreenMobility” or the “Company”), has today resolved to grant warrants in the Company for the purpose of: Ensuring that shareholders, the Executive Management and other management employees of the Company have the same interests, and that everyone makes a special effort for the value creation in the Company and its subsidiaries.Retaining the Executive Management and management employees of the Company.Granting warrants to the Board of Directors as authorized at the 2021 Annual General Meeting but not yet granted Warrants granted will generally be subject to the existing warrant programs as publicized in company announcement no. 41 on November 19th, 2019 and in company announcement no. 64 on September 29th 2020 with certain deviations. The total issuance of warrants is in accordance with the resolutions passed at the Annual General Meetings held on

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results23.3.2023 22:00:00 CET | Press release

Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 full-year financial results on Thursday, March 30, 2023. Inventiva’s 2022 full-year financial results will be published on Wednesday, March 29, 2023 at 4:00 pm (New York), 10:00 pm (Paris). Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, onThursday, March 30, 2023, at8:00 am (New York)

Nyxoah Announces a $15 Million Private Placement Financing23.3.2023 21:05:00 CET | Press release

INSIDE INFORMATION REGULATED INFORMATION NyxoahAnnounces a $15 Million Private Placement Financing Mont-Saint-Guibert, Belgium – March 23, 2023, 9:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced a €13.35 million private placement financing from the sale of 2,047,544 new ordinary shares at a price per share of €6.52 (approximately U.S. $7.10 at current exchange rates), the closing price on Euronext Brussels on March 23, 2023. Gross proceeds total €13.35 million (approximately U.S. $15 million at current exchange rates) and will be used for general corporate purposes. The closing is expected to occur on or about March 30, 2023, subject to customary closing conditions. The private placement financing includes historical Nyxoah shareholders, notably ResMed and Robert Taub, Nyxoah’s Founde